Slide 1: Q2 FY2021 Financial Results
Q2 FY2021 Financial Results May 5, 2021
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securit
Slide 3: United in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen drives innovative partnerships with global manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.
Slide 4: Overview
Overview Solid Q2 Positioned for long- Fiscal 2021 performance term, sustainable guidance update growth • Pharmaceutical • Strengthening • Updated fiscal 2021 distribution growth global portfolio of guidance reflects driven by specialty solutions strong business product sales • Supporting fundamenta
Slide 5: Q2 FY2021 financial results
Q2 FY2021 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $49.2B $49.2B % Change (Year-over-Year) 3.7% 3.7% Gross profit $1.5B $1.5B % Change 10.5% 6.7% Operating expenses $909M $806M % Change (15.7)% 8.1% Operating income $624M $707M % Change 101.7% 5.2% Interest expense, n
Slide 6: Pharmaceutical Distribution Services segment
Q2 FY2021 financial results Pharmaceutical Distribution Services segment Q2 FY2021 Q2 FY2020 Revenue $47.1B $45.6B Operating income $589M $563M Percentages of revenue Gross profit 2.39% 2.32% Operating expenses 1.14% 1.08% Operating income 1.25% 1.24% ▪ Revenue increase driven by strong specialty pr
Slide 7: Other — Global Commercialization Services & Animal Health
Q2 FY2021 financial results Other — Global Commercialization Services & Animal Health Q2 FY2021 Q2 FY2020 Revenue $2.1B $1.9B Operating income $123M $108M Percentages of revenue Gross profit 18.81% 19.15% Operating expenses 12.92% 13.38% Operating income 5.89% 5.77% ▪ Other includes MWI, World Couri
Slide 8: FY2021 guidance
FY2021 guidance Updated guidance does not include any contribution from the proposed Alliance Healthcare acquisition Expectations on an adjusted (non-GAAP) basis1 Revenue High-single digit percent growth Diluted earnings per share $8.45 to $8.60 Operating expense High-single digit percent growth Ope
Slide 9: Purpose fuels performance
Purpose fuels performance Why we exist We are united in our responsibility to create healthier futures Our key strengths Best customer base Leader in specialty Innovation mindset Corporate stewardship distribution and commercialization Our growth strategies Customer focus Expand on Execution and inn
Slide 10: Next evolution of enhancing ability to provide innovative and global healthcare solutions
Next evolution of enhancing ability to provide innovative and global healthcare solutions Acquisition of Alliance Healthcare and extension of U.S. partnership with Walgreens Strategic highlights Financial impacts • Enhances scale and margin profile • Acquisition expected to generate high-teens % adj
Slide 11: Appendix
Appendix
Slide 12: Non-GAAP financial measures note
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: Non-GAAP financial measures note
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the 13 Company’s most recent Current Report on Form 8-K furnished under Item 2.02.
Slide 14: Contact
Contact Bennett S. Murphy Senior Vice President Investor Relations bmurphy@amerisourcebergen.com